Diagnosis of duct disruption and assessment of pancreatic leak with dynamic secretin-stimulated MR cholangiopancreatography.
OBJECTIVE
The management of pancreatic duct disruption is complex and depends on several factors including the cause, morphology, and degree of disruption. ERCP can show duct disruption in as many as 75% of patients but is invasive and cannot detect disruption beyond an obstruction. We studied the role of secretin MR cholangiopancreatography in patients with suspected pancreatic duct disruption.


CONCLUSIONS
Secretin MR cholangiopancreatography is a safe, noninvasive test that can provide additional useful information about duct integrity and facilitate management.
Gillams
A R
AR
Department of Medical Imaging, The Middlesex Hospital and University College London Medical School, Mortimer St., London W1T 3AA, England.
Kurzawinski
T
T
Lees
W R
WR
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002760:Cholangiopancreatography, Endoscopic Retrograde / Q000009:adverse effects; D049448:Cholangiopancreatography, Magnetic Resonance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010183:Pancreatic Ducts / Q000293:injuries / Q000473:pathology*; D010195:Pancreatitis / Q000473:pathology*; D012633:Secretin
D012633:Secretin